Measuring the Preferences of Homeless Women for Cervical Cancer Screening Interventions: Development of a Best-Worst Scaling Survey [0.03%]
无家可归妇女宫颈癌筛查干预措施的选择偏好测量：最佳- WorstScaling调查的制订
Eve Wittenberg,Monica Bharel,Adrianna Saada et al.
Eve Wittenberg et al.
Objective: Despite having multiple risk factors, women experiencing homelessness are screened for cervical cancer at a lower rate than women in the general US population. We report on the design of a stated preference stu...
Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey [0.03%]
加拿大孤儿药社会价值测量的挑战：来自声明偏好的调查见解
Nick Dragojlovic,Shirin Rizzardo,Nick Bansback et al.
Nick Dragojlovic et al.
Background: Expensive drugs for rare diseases (i.e. orphan drugs) often do not meet traditional cost-effectiveness criteria and thus put further strain on limited healthcare budgets. Failing to provide medically necessary...
Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle [0.03%]
制定患者导向的政策框架以管理孤儿药和超孤儿药在整个生命周期中的使用
Devidas Menon,Tania Stafinski,Andrea Dunn et al.
Devidas Menon et al.
Introduction: Policy decisions related to orphan and ultra-orphan drugs challenge traditional decision-making processes and often frustrate those affected by them. In general, these drugs are associated with significant u...
Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis [0.03%]
杜氏肌营养不良新兴治疗方案的护理人员偏好比较：最佳- Worst Scaling 与联立分析法之比较
Ilene L Hollin,Holly L Peay,John F P Bridges
Ilene L Hollin
Background: Through Patient-Focused Drug Development, the US Food and Drug Administration (FDA) documents the perspective of patients and caregivers and are currently conducting 20 public meetings on a limited number of d...
Comparative Study
The patient. 2015 Feb;8(1):19-27. DOI:10.1007/s40271-014-0104-x 2015
Durhane Wong-Rieger,William Claxton,Richard Vines et al.
Durhane Wong-Rieger et al.
Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity? [0.03%]
患者参与罕见病及超罕见病药物决策以减少不确定性：一个难得的机遇吗？
Devidas Menon,Tania Stafinski,Andrea Dunn et al.
Devidas Menon et al.
Introduction: Uncertainty influences the amount of risk in decision making, and is typically related to clinical benefit, value for money, affordability, and/or adoption/diffusion of the technology (e.g., drug, device, pr...
Consumers and Carers Versus Pharmacy Staff: Do Their Priorities for Australian Pharmacy Services Align? [0.03%]
消费者与护理人员 versus 药房工作人员：澳大利亚药房服务的重点一致吗？
Sara S McMillan,Fiona Kelly,Adem Sav et al.
Sara S McMillan et al.
Background: Health professionals, including pharmacists, are encouraged to meet the needs of their consumers in an efficient and patient-centred manner. Yet, there is limited information as to what consumers with chronic ...
Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program [0.03%]
多发性硬化症患者对达法普林治疗步行障碍的视角及体验：Step Together项目报告
Heidi Crayton,Matthew Sidovar,Stanley Wulf et al.
Heidi Crayton et al.
Background: Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the ...
Computer-Based Clinical Decision Support Systems and Patient-Reported Outcomes: A Systematic Review [0.03%]
基于计算机的临床决策支持系统与患者报告结果之间的关系：一项系统综述研究
David Blum,Sunil X Raj,Rolf Oberholzer et al.
David Blum et al.
Background: Evidence-based treatment guidelines embedded in computer-based clinical decision support systems (CCDSS) may improve patient-reported outcomes (PRO). We systematically reviewed the literature for content and a...
Adopting a Sustainable Community of Practice Model when Developing a Service to Support Patients with Epidermolysis Bullosa (EB): A Stakeholder-Centered Approach [0.03%]
以患者为中心的开发服务支持表皮松解症社区的可持续模式的方法论研究
Rosemary Joan Gowran,Avril Kennan,Siobhán Marshall et al.
Rosemary Joan Gowran et al.
Objectives: Epidermolysis bullosa (EB) is a rare, genetic skin condition that is complicated, distressing, and painful and permeates every aspect of patients' lives. Support services are essential for meeting the primary ...